We retina specialists are lucky enough to be in a position to continue to treat patients during the pandemic. Yes, protocols have changed. Yes, volumes have dropped. And yes, altered treatment patterns may affect patients. All of these are concerning. It is worth mentioning, though, that in the aggregate we provided (and can still provide) a level of care that some of our colleagues elsewhere in medicine were unable (or not allowed) to administer.
We have dedicated the past three issues of Retina Today to the COVID-19 crisis—and for good reason. The events of 2020 will forever reshape medicine. To ignore this public health emergency would have been editorial malpractice. As our understanding of the virus evolves, the need for continued coverage persists. Still, as we get back to semi-normal practice, we have decided to return a portion of our focus to the practice of retina itself. For our next several issues, we’ll be covering the art of retina during the pandemic.
In this issue’s suite of cover articles, we’ve included some COVID-19 topics (such as two retina fellows’ perspectives on how their training has been affected by the crisis) some diabetic eye disease topics (such as a contrasting review of two clinical trials for drugs that address diabetic eye disease), and some retina-during-COVID topics (such as a piece on how to treat diabetic eye disease during the pandemic). Among our jewels this issue: a photo essay from Nuha Kapatayes, BS, and Brian C. Joondeph, MD, MPS, in which they share what they believe to be the first reported case of a patient presenting with central retinal vein occlusion associated with COVID-19.
As always, our columns are worth investigating. Matthew R. Starr, MD, interviews Carl D. Regillo, MD, about the latest data regarding dry AMD therapy. Daniel L. Chao, MD, PhD; Arshad M. Khanani, MD, MA; and Charles C. Wykoff, MD, PhD, summarize the COOL-2 trial, which may lead to a new type of anesthetic for intravitreal injection. And the Eyetube team checks in with the latest videos from around the globe.
A final note: Check out Retina Today’s new website. Its sharper, cleaner articulation of the publication’s content is designed for mobile reading and quick searches. We think you’ll like it. While you’re there, sign up for the publication’s print version or opt in to our emails so that you can stay up-to-date on all things Retina Today.